[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Transcend Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":43},"100628058",false,"NCT07456696","An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD","EMPOWER-1","Inclusion Criteria:\n\n* Meets the DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months.\n* Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy.\n* Proficient in communication (verbal and reading) to complete interviews and written questionnaires.\n* Free from any other clinically significant illness or disease.\n\nExclusion Criteria:\n\n* Primary diagnosis of any other DSM-5 disorder.\n* Body mass index (BMI) \\\u003C18 kg\u002Fm2 or ≥40 kg\u002Fm2.\n* Unable to refrain from nicotine use for at least 8 hours.\n* Use of prohibited concomitant medications or therapies.\n* Current or previous history of clinically significant cardiovascular (including current uncontrolled hypertension) \u002F cerebrovascular conditions.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD.\n\nEligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.",[26],"Post Traumatic Stress Disorder",[28,14,29,30,31],"PTSD","Transcend Therapeutics","TSND-201","Neuroplastogen","RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":36},"2026-04-02",{"date":40,"type":20},"2027-12",{"name":29,"class":42},"INDUSTRY",32,""]